Using Metabolomic Signatures for Risk Stratification and Personalized Treatment of Bladder Cancer
Abstract
Approximately 25-39 percent of patients with MIBC harbor disease which is not sensitive to chemotherapy. This appreciation that some bladder cancers are more susceptible to chemotherapy supports research of tumor classification to help identify which patients stand to benefit the most from NAC. We have demonstrated in preliminary studies that metabolic characterization into high and low glycolytic tumors may risk-stratify for bladder cancer survival particularly in the more aggressive basal molecular subtype population. We hypothesize use of metabolic characterization of bladder cancer can both predict tumor sensitivity to neoadjuvant chemotherapy as well as characterize treatment response in patients. We have to date in year 1 even despite some delays due to COVID surges and workforce shortages established the human and animal research regulatory infrastructure as well as recruited our first 8 patients to study. The work continues now on pace for good progress and with promising early results presented in this annual review.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1191102
Entities
People
- David Mcconkey
- Mohummad Siddiqui
- Nagireddy Putluri
Organizations
- Johns Hopkins University